Cost-Effectiveness Analysis of <sup>177</sup>Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective.
Gogebakan KC; Kunst N; Ghodsi A; Owens L; Iravani A; Etzioni R · 2026 · Journal of nuclear medicine : official publication, Society of Nuclear Medicine
WASTE classifies this as Methods Dead-End · AI classification, approximate
A method or design hit a limitation — check whether the same constraint applies to your setup.
The finding, in one line
“The TheraP trial demonstrated that 177 Lu-PSMA-617 improved progression-free survival (PFS) compared with cabazitaxel, with no significant difference in overall survival (OS).”
Abstract (excerpt)
The TheraP trial demonstrated that 177 Lu-PSMA-617 improved progression-free survival (PFS) compared with cabazitaxel, with no significant difference in overall survival (OS). However, 177 Lu-PSMA-617 was associated with fewer severe…
Excerpt shown for reference under fair use — read the full paper at the publisher.
Hosted by the publisher — may require access.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
Negative / Null Result ReportDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
Negative / Null Result ReportStenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis
Negative / Null Result ReportEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Replication FailureA Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Negative / Null Result ReportSpironolactone for Heart Failure with Preserved Ejection Fraction
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: Europe PMC · DOI 10.2967/jnumed.125.271825